CapVest’s Curium shelves potential $3bn sale amid market volatility
As the JPM and Rothschild process for the French nuclear medicine company is put on hold, attention shifts to Webster Equity-backed PharmaLogic, sources told PE Hub.
Nearly there!
A verification email is on its way to you. Please check your spam or junk folder just in case.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: subscriptions@pei.group .-
Sign in or Register
-
Issues with signing in? Click here
Don't have an account? Register now
-
